The Latest Zantac Update
Whether you’re a patient, health care provider or consumer, it’s important to know about the latest update in the Zantac controversy. Below are some of the issues to consider.
NDMA is a known carcinogen and has been found in a variety of products. It is found in foods, cleansers, and shampoos. It is also found in some types of medications. In fact, NDMA is believed to cause cancer in humans and animals.
In 2016, a study showed that people taking Zantac have over 400 times more NDMA in their urine than the legal limit. This study has led to several lawsuits against the manufacturer of Zantac, Sanofi. NDMA is a chemical that is known to cause cancer, so the FDA is calling on the public to stop using Zantac.
There are many other medications available to consumers, including other heartburn medications. However, these medications do not contain the same NDMA. If you are considering stopping taking your medication, it is best to consult your doctor first.
Zantac is a ranitidine medication that is used to treat acid reflux. This medication is used by millions of people in the United States. It is also found in a variety of brand names. It has been shown to reduce heartburn symptoms.
Although NDMA is a known carcinogen, it is not produced in the United States. It was formerly used as a lubricant and an antioxidant. It was also used in liquid rocket fuels. It has also been found in cured meats.
NDMA is classified as a probable human carcinogen by the Environmental Protection Agency and the World Health Organization. Although there are no current studies proving NDMA’s ability to cause cancer, it is known that the compound can affect human DNA. This leads to genetic mutations and repeated DNA damage.
NDMA is also a known environmental contaminant. It has been found in pesticides and drinking water sources. It has been associated with tumors in mice. It has also been found in soil and air samples around production facilities.
Although NDMA is not currently being produced in the United States, it is present in a wide variety of products. It is also found in foods and water. Its safety in human beings has been extensively studied. It is believed to increase the risk of certain types of cancer in humans, including stomach and bladder cancers.
Thousands of lawsuits have been filed over the carcinogenic substance, NDMA, which is found in Zantac. The plaintiffs allege that the drug companies failed to warn them about the potential for cancer.
The first four bellwether trials are scheduled for California. The first one will be in Oakland on February 13, 2023. The second will be in California JCCP on February 6, 2023. The third will be in California JCCP on May 1, 2023. The fourth will be in California JCCP on August 7, 2023.
Bellwether trials are used by the parties to assess the value of a case. They can also indicate whether a settlement will be reached outside of court. The parties can ask basic questions to the Zantac makers.
There are over 2,000 Zantac lawsuits filed in Florida and California. They have not produced settlements yet. The defendants in Zantac lawsuits deny any wrongdoing.
The Zantac MDL is a multidistrict lawsuit. It is presided over by Judge Robin L. Rosenberg in the Southern District of Florida. He outlined the procedures for the bellwether trials in his pretrial order.
A bellwether trial is a test case in mass tort litigation. It is used by the plaintiffs to determine whether a trial will be successful. If the plaintiffs win, the case will likely lead to a settlement. The defendants may be more willing to settle if they see the jury verdict is in their favor.
The process for selecting bellwether cases is outlined in Pretrial Order #69. The parties will narrow the pool of cases to four by March 11, 2022. They will alternate choosing the second bellwether trial. The parties will then continue to select bellwether cases until the global settlement is reached.
In order to qualify for the bellwether pool, the plaintiff must allege one of the five cancers designated by the leadership counsel. They must also not have citizenship issues that could call into question the federal jurisdiction of the case.
Defendants in Zantac lawsuits may choose to file their own cases instead of letting them be selected by the plaintiffs. This could lead to a delay in recovery. Defendants could also choose to make settlement offers that are low.
List of forms of cancer
Several Zantac related lawsuits have made their way through the court system. The most recent of these suits is pending approval in MDL 2924. While some Zantac patients might be unwitting participants in a Zantac related car wreck, others may be pleasantly surprised to find out that they weren’t the only ones who suffered from a plethora of adverse drug reactions and related hospitalizations. While the jury is out in this case, the Zantac brand may be in good hands.
Despite its best efforts, Zantac is not without its share of controversy. For one thing, it’s been found to be contaminated with the cancer-causing neurotoxin NDMA, which is a shame. Although no one knows for sure what exactly NDMA is, a number of studies have found that it can be carcinogenic. The drug’s maker, Sanofi, has been forced to issue a warning to patients, while its competitor, AstraZeneca, is under investigation. Several of its other drugs have been recalled, while others have been rebranded.
The best news is that patients who are unlucky enough to have ingested the prescription medicine may be able to take the high road and opt for alternative medications. Until more information is made public, many are steering clear of the drug. Besides, the FDA allows only certain amounts of carcinogenic compounds to be sold in the U.S., and if the drug manufacturer isn’t making a big deal out of it, patients may have no choice but to take their business elsewhere.
Legal claims filed in other jurisdictions
Thousands of lawsuits have been filed in various states in the US and in other jurisdictions, all alleging that Zantac, the generic drug used for the treatment of gastrointestinal disorders, causes cancer. Several countries have also taken action to ban or restrict sales of Zantac.
The latest update to the Zantac Lawsuit Registry indicates that there are more than 2,000 plaintiffs bringing lawsuits against the manufacturers of Zantac. While the number of active cases is small, the numbers are expected to increase. Some of the lawsuits are expected to be dismissed. However, a large number of plaintiffs have decided to file claims in order to avoid the statute of limitations.
Zantac lawsuits accuse the manufacturers of the drug, Sanofi, GlaxoSmithKline (GSK), Boehringer Ingelheim, and Chattem, of knowingly manufacturing the drug at unsafe levels of N-nitrosodimethylamine (NDMA). NDMA is known to cause cancer. Several animal studies have shown that moderate to high levels of NDMA in water or food can cause liver damage after a few weeks. Acute, high-dose ingestion of NDMA has also caused internal bleeding and liver damage.
Several lawsuits have been filed in Illinois. One of the lawsuits was set to be the first Zantac cancer case to reach trial in the US. However, the case settled for $500,000 late in the process.
Plaintiffs have filed motions to depose a Sanofi IT employee. They believe this employee may have firsthand knowledge of email deletions. Sanofi has insisted that there is no scientific evidence that Zantac causes cancer.
The plaintiffs’ attorneys are alleging that Sanofi has been deliberately deleting emails that may be relevant to the lawsuit. They also argue that Sanofi has engaged in delay tactics during the discovery phase of the lawsuit. The judge has scheduled a hearing to allow both sides to discuss the effects of the new evidence.
The Zantac Lawsuit Registry was created to enable prospective plaintiffs to join the litigation without actually filing a civil lawsuit. In order to take part, potential plaintiffs must fill out a comprehensive information sheet. They also must authorize the release of their medical records.
Some lawyers have expressed concern that zantac settlement amounts are not high enough. They believe that a global settlement would be higher. Refer to this page for the latest zantac update.